Fujifilm Diosynth Biotechnologies Opens New Manufacturing Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fujifilm Diosynth Biotechnologies Opens New Manufacturing Facility


Fujifilm Diosynth Biotechnologies formally opened its new mammalian cell culture cGMP manufacturing facility in the United Kingdom, the company reported in a press release. The new facility, which was built and commissioned in less than 15 months, is the first facility of its kind in the UK that was purpose-built to use primarily single-use technologies for both upstream and downstream operations. It has initially been commissioned with 200-L and 1000-L bioreactors, with a 2000-L bioreactor planned for 2014. The company is working on its first customer project for the facility.

This new capacity is the latest in a series of investments at both Fujifilm Diosynth Biotechnologies’ UK and Research Triangle Park, NC, US facilities over the past two years. New cell-line development and process-development laboratories have been set up at both sites, and a 1000-L single-use bioreactor was installed at the US facility two years ago to supplement its 2000-L stainless-steel train for the GMP production of mammalian cell-culture biopharmaceuticals.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here